Agilent Technologies Inc.. (3/30/20). "Press Release: Agilent Announces New Class 1 Triple Quadrupole LC/MS System. Purpose-built and Validated for Clinical Laboratories". Santa Clara, CA.

	Organisation	Agilent Technologies Inc. (NYSE: A)
	Organisation 2	OpAns LLC (Optimzied Analytical Solutions)
	Product	K6460S Clinical Edition TQ LC/MS system
	Product 2	MassHunter software
	Person	Benefiel, Monty (Agilent 201506 Division General Manager Mass Spec before 201302 VP for gas phase systems)
	Person 2	Lewis, Ken (OpAns 201304 President)

Agilent Technologies Inc. (NYSE: A) today introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs.

Agilent’s next-generation clinical edition triple quadrupole LC/MS system, the K6460S, is listed as a Class I medical device with the U.S. Food and Drug Administration. The system includes a preconfigured liquid chromatograph and mass spectrometer, as well as the clinical edition of Agilent MassHunter software, which provides an easy-to-use and intuitive submission-to-reporting workflow.

When performing diagnostic assays, the K6460S provides the specificity and selectivity that clinical labs require, delivering robust results with more accuracy, and increasing the reliability of target compound detection in complex matrices.

“We are pleased to announce the launch of the K6460S, our newly validated LC/MS system in the United States,” said Monty Benefiel, vice president and general manager of Agilent's Mass Spectrometry Division. “Agilent has a strong reputation in providing reliable and routine solutions to clinical laboratories. We believe that the strength and robustness of our technologies, combined with our depth of expertise in our services and support offerings, makes Agilent a powerful partner for clinical diagnostic labs.”

“Using TQ LC/MS increases the specificity, selectivity, and accuracy of many clinical diagnostic assays compared to traditional binding assays,” said Ken Lewis, chief executive officer of OpAns, LLC. “The fully validated Agilent K6460S is a robust and reliable platform that boosts productivity via technology purpose-built for diagnostic workflows.”

It was also announced in January 2020 that the Agilent LC-MS/MS had been approved by China's national drug administration (NMPA) for use in the China domestic clinical diagnosis market.

Agilent is a leader in providing IVD medical devices to improve the quality of health care globally and has driven investment in this key area to develop and launch robust, reliable LC-MS/MS IVD systems. These instruments improve and simplify the analysis of samples and address specific workflows to expedite the efficacy of clinical diagnostics.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Record changed: 2023-06-05